Adult T-cell leukemia-lymphoma
Conditions
Interventions
None listed
Sponsors
Nagoya City University Hospital
SRL Medisearch Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Subjects who are diagnosed as adult T-cell leukemia-lymphoma and are scheduled for administration of mogamulizumab. 2) Subjects who are 20 years or older. 3) Subjects who have given written voluntary informed consent to participate in the present study 4) Subjects who have a result of HLA-A typing (A physician can make a decision of test item regarding immune monitoring)
Exclusion criteria
Exclusion criteria: 1) Subjects with a history of receiving mogamulizumab 2) Subjects with a history of receiving allogeneic hematopoietic stem cell transplantation. 3) Subjects who are determined to have any serious difficulties for 6 months immune monitoring after their enrollment by the physician. 4) Subjects who are pregnant, of childbearing potential, or lactating. 5) Subjects who are determined to be unsuitable for enrolled in the present study by the physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the immune responses such as the number of CD4/CD8 positive T cells, NK cells, B cells, Treg cells, and HTLV-1 specific cytotoxic T cells in blood following mogamulizumab containing treatment in the ATL patients. | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy of mogamulizumab containing treatment Adverse events of mogamulizumab containing treatment Overall survival | — |
Countries
Japan
Contacts
Public ContactShigeru Kusumoto
Nagoya City University Graduate School of Medical Sciences Hematology and Oncology
Outcome results
None listed